6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Advancements and application prospects of three-dimensional models for primary liver cancer: a comprehensive review

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Primary liver cancer (PLC) is one of the most commonly diagnosed cancers worldwide and a leading cause of cancer-related deaths. However, traditional liver cancer models fail to replicate tumor heterogeneity and the tumor microenvironment, limiting the study and personalized treatment of liver cancer. To overcome these limitations, scientists have introduced three-dimensional (3D) culture models as an emerging research tool. These 3D models, utilizing biofabrication technologies such as 3D bioprinting and microfluidics, enable more accurate simulation of the in vivo tumor microenvironment, replicating cell morphology, tissue stiffness, and cell-cell interactions. Compared to traditional two-dimensional (2D) models, 3D culture models better mimic tumor heterogeneity, revealing differential sensitivity of tumor cell subpopulations to targeted therapies or immunotherapies. Additionally, these models can be used to assess the efficacy of potential treatments, providing guidance for personalized therapy. 3D liver cancer models hold significant value in tumor biology, understanding the mechanisms of disease progression, and drug screening. Researchers can gain deeper insights into the impact of the tumor microenvironment on tumor cells and their interactions with the surrounding milieu. Furthermore, these models allow for the evaluation of treatment responses, offering more accurate guidance for clinical interventions. In summary, 3D models provide a realistic and reliable tool for advancing PLC research. By simulating tumor heterogeneity and the microenvironment, these models contribute to a better understanding of the disease mechanisms and offer new strategies for personalized treatment. Therefore, 3D models hold promising prospects for future PLC research.

          Related collections

          Most cited references107

          • Record: found
          • Abstract: found
          • Article: not found

          Hepatocellular carcinoma

          Hepatocellular carcinoma appears frequently in patients with cirrhosis. Surveillance by biannual ultrasound is recommended for such patients because it allows diagnosis at an early stage, when effective therapies are feasible. The best candidates for resection are patients with a solitary tumour and preserved liver function. Liver transplantation benefits patients who are not good candidates for surgical resection, and the best candidates are those within Milan criteria (solitary tumour ≤5 cm or up to three nodules ≤3 cm). Image-guided ablation is the most frequently used therapeutic strategy, but its efficacy is limited by the size of the tumour and its localisation. Chemoembolisation has survival benefit in asymptomatic patients with multifocal disease without vascular invasion or extrahepatic spread. Finally, sorafenib, lenvatinib, which is non-inferior to sorafenib, and regorafenib increase survival and are the standard treatments in advanced hepatocellular carcinoma. This Seminar summarises the scientific evidence that supports the current recommendations for clinical practice, and discusses the areas in which more research is needed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

            In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The tumor microenvironment

              A tumor is not simply a group of cancer cells, but rather a heterogeneous collection of infiltrating and resident host cells, secreted factors and extracellular matrix. Tumor cells stimulate significant molecular, cellular and physical changes within their host tissues to support tumor growth and progression. An emerging tumor microenvironment is a complex and continuously evolving entity. The composition of the tumor microenvironment varies between tumor types, but hallmark features include immune cells, stromal cells, blood vessels, and extracellular matrix. It is believed that the "tumor microenvironment is not just a silent bystander, but rather an active promoter of cancer progression" (Truffi et al., 2020). Early in tumor growth, a dynamic and reciprocal relationship develops between cancer cells and components of the tumor microenvironment that supports cancer cell survival, local invasion and metastatic dissemination. To overcome a hypoxic and acidic microenvironment, the tumor microenvironment coordinates a program that promotes angiogenesis to restore oxygen and nutrient supply and remove metabolic waste. Tumors become infiltrated with diverse adaptive and innate immune cells that can perform both pro- and anti- tumorigenic functions (Figure 1). An expanding literature on the tumor microenvironment has identified new targets within it for therapeutic intervention.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Bioeng Biotechnol
                Front Bioeng Biotechnol
                Front. Bioeng. Biotechnol.
                Frontiers in Bioengineering and Biotechnology
                Frontiers Media S.A.
                2296-4185
                21 December 2023
                2023
                : 11
                : 1343177
                Affiliations
                [1] 1 First Central Clinical College of Tianjin Medical University , Tianjin, China
                [2] 2 Nankai University of Medicine College , Tianjin, China
                [3] 3 Department of Pharmacology , Shenyang Pharmaceutical University , Shenyang, China
                [4] 4 Department of Hepatobiliary Surgery , Tianjin First Central Hospital , Tianjin, China
                [5] 5 National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine , Tianjin Institute of Pharmaceutical Research , Tianjin, China
                [6] 6 Research Unit for Drug Metabolism , Chinese Academy of Medical Sciences , Beijing, China
                Author notes

                Edited by: Zhaobin Guo, Shanghai University of Traditional Chinese Medicine, China

                Reviewed by: Zheng Zhong, Lyell Immunopharma, Inc., United States

                Alessandro Poggi, San Martino Hospital (IRCCS), Italy

                *Correspondence: Tao Cui, cuitao0909@ 123456126.com ; Yamin Zhang, 5020200824@ 123456nankai.edu.cn
                [ † ]

                These authors have contributed equally to this work and share first authorship

                Article
                1343177
                10.3389/fbioe.2023.1343177
                10771299
                38188493
                c8322b2d-b9ec-4ea5-9abc-7d0ea75ddcdd
                Copyright © 2023 Zhu, Cheng, Liu, Yang, Han, Cui and Zhang.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 23 November 2023
                : 11 December 2023
                Funding
                The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This review was supported by the National Natural Science Foundation of China (82372194 and 82204546), the Tianjin Natural Science Foundation (21JCYBJ00050 and 21JCYBJC00320), and the Tianjin Health Science and Technology Project (TJWJ2021ZD002, TJWJ2023MS012, TJWJ2023QN034, and TJWJ2023QN028).
                Categories
                Bioengineering and Biotechnology
                Review
                Custom metadata
                Organoids and Organ-On-A-Chip

                primary liver cancer,three-dimensional models,bioprinting technology,microfluidic technology,patient-derived xenograft

                Comments

                Comment on this article